COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon

por Hasselbalch, H.C., Skov, V., Kjær, L., Ellervik, C., Poulsen, A., Poulsen, T.D., Nielsen, C.H.
Publicado 2021